北京民海生物科技有限公司抗柯萨奇病毒A16型的抗体及其制备方法和应用专利获授权（生物医药专利快讯）_老虎社区_美港股上老虎

北京民海生物科技有限公司抗柯萨奇病毒A16型的抗体及其制备方法和应用专利获授权（生物医药专利快讯）

DoNews2025-10-18

天眼查App显示，2025-10-17，“抗柯萨奇病毒A16型的抗体及其制备方法和应用”（patentName）正式进入专利权的授权阶段。申请人为北京民海生物科技有限公司，该项生物医药专利涉及抗柯萨奇病毒A16型（CV-A16）的抗体研发与应用。据专利信息显示，该抗体或其抗原结合片段可特异性结合并中和CV-A16毒株及其抗原，对CV-A16感染动物具有良好的保护作用，技术效果数据提升达显著优化。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2576927040?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-18 14:14","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2576927040","market":"us","top_or_hot":-1,"title":"北京民海生物科技有限公司抗柯萨奇病毒A16型的抗体及其制备方法和应用专利获授权（生物医药专利快讯）","media":"DoNews","content":"<div>\n<p>天眼查App显示，2025-10-17，“抗柯萨奇病毒A16型的抗体及其制备方法和应用”（patentName）正式进入专利权的授权阶段。申请人为北京民海生物科技有限公司，该项生物医药专利涉及抗柯萨奇病毒A16型（CV-A16）的抗体研发与应用。据专利信息显示，该抗体或其抗原结合片段可特异性结合并中和CV-A16毒株及其抗原，对CV-A16感染动物具有良好的保护作用，技术效果数据提升达显著优化。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018141626a6bfec47&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>北京民海生物科技有限公司抗柯萨奇病毒A16型的抗体及其制备方法和应用专利获授权（生物医药专利快讯）</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n北京民海生物科技有限公司抗柯萨奇病毒A16型的抗体及其制备方法和应用专利获授权（生物医药专利快讯）\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-18 14:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018141626a6bfec47&s=b><strong>DoNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>天眼查App显示，2025-10-17，“抗柯萨奇病毒A16型的抗体及其制备方法和应用”（patentName）正式进入专利权的授权阶段。申请人为北京民海生物科技有限公司，该项生物医药专利涉及抗柯萨奇病毒A16型（CV-A16）的抗体研发与应用。据专利信息显示，该抗体或其抗原结合片段可特异性结合并中和CV-A16毒株及其抗原，对CV-A16感染动物具有良好的保护作用，技术效果数据提升达显著优化。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018141626a6bfec47&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018141626a6bfec47&s=b","article_id":"2576927040","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018141626a6bfec47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2576927040","pubTimestamp":1760768043,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"天眼查App显示，2025-10-17，“抗柯萨奇病毒A16型的抗体及其制备方法和应用”正式进入专利权的授权阶段。申请人为北京民海生物科技有限公司，该项生物医药专利涉及抗柯萨奇病毒A16型的抗体研发与应用。据专利信息显示，该抗体或其抗原结合片段可特异性结合并中和CV-A16毒株及其抗原，对CV-A16感染动物具有良好的保护作用，技术效果数据提升达显著优化。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4082":"医疗保健设备","CV":"CapsoVision, Inc."},"translate_title":"Beijing Minhai Biotechnology Co., Ltd. 's anti-Coxsackie virus A16 antibody and its preparation method and application patent were authorized (Biomedical Patent News)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CV":0.72},"content_text":"天眼查App显示，2025-10-17，“抗柯萨奇病毒A16型的抗体及其制备方法和应用”（patentName）正式进入专利权的授权阶段。申请人为北京民海生物科技有限公司，该项生物医药专利涉及抗柯萨奇病毒A16型（CV-A16）的抗体研发与应用。据专利信息显示，该抗体或其抗原结合片段可特异性结合并中和CV-A16毒株及其抗原，对CV-A16感染动物具有良好的保护作用，技术效果数据提升达显著优化。发明人为张改梅;陈磊;赵丽丽;谢学超;曹慧佼;顾美荣;李国顺;刘建凯。本发明提供的抗体重链CDR1、CDR2、CDR3氨基酸序列如SEQ ID NO.1-3所示，轻链CDR1、CDR2、CDR3如SEQ ID NO.4-6所示，可用于CV-A16疫苗抗原性与免疫原性评价、感染诊断及预防或治疗药物开发。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}